City

Nanjing (2)

Tianjin (1)

Condition

HRD (4)

Ovarian Cancer (2)

Advanced Solid Tumors (1)

BRCA Mutation (1)

Cholangiocarcinoma (1)

Metastatic Cancer (1)

PARP Inhibitor (1)

Platinum-sensitive Ovarian Cancer (1)

Overall Status

Not yet recruiting (2)

Unknown status (1)

Withdrawn (1)

Sign in for free

Phase

phase 1 (1)

phase 2 (1)

Sponsor

Xiaoxiang Chen (2)

Hubei Biological Medicine Industrial Technology Institute Co., Ltd. (1)

Walid Shaib, MD (1)

Collaborator

Emory University (1)

GlaxoSmithKline (1)

Intervention

dostarlimab (1)

hwh340 tablet (1)

niraparib (1)

parp inhibitor (1)

Study Documents

Intervention Type

drug (3)

Funder Type

Other (4)

Study Type

Interventional (2)

Observational (2)

hrd

Showing 1 - 4 of 4

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

LAST UPDATED

HRD, Cholangiocarcinoma, Metastatic Cancer Trial (Niraparib, Dostarlimab)

Withdrawn

HRD
+2 more

(no location specified)

Jun 23, 2022

Variance of HRD From Paired Ovarian Cancer

Not yet recruiting

Ovarian Cancer
+2 more

Nanjing, Jiangsu, China

Xiaoxiang Chen

Sep 25, 2021

Homologous Recombination Deficiency in Chinese Ovarian Cancer

Not yet recruiting

Ovarian Cancer
+2 more

PARP inhibitor

Nanjing, Jiangsu, China

Xiaoxiang Chen, MD,PhD

Sep 4, 2021

Advanced Solid Tumors, HRD, BRCA Mutation Trial in Tianjin (HWH340 tablet)

Unknown status

Advanced Solid Tumors
+2 more

HWH340 tablet

Tianjin, Tianjin, China

Tianjin medical university cancer insititute & hospital

Feb 12, 2020